Van ECK Associates Corp Purchases 22,718 Shares of Illumina, Inc. (NASDAQ:ILMN)

Van ECK Associates Corp lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 17.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 152,265 shares of the life sciences company's stock after buying an additional 22,718 shares during the period. Van ECK Associates Corp owned approximately 0.10% of Illumina worth $20,347,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the fourth quarter worth $32,000. Versant Capital Management Inc increased its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after buying an additional 141 shares during the last quarter. Spire Wealth Management increased its holdings in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after acquiring an additional 97 shares during the last quarter. Finally, Private Trust Co. NA lifted its position in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after buying an additional 212 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Citigroup downgraded Illumina from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Barclays lowered shares of Illumina from an "equal weight" rating to an "underweight" rating and decreased their price target for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. Finally, UBS Group lifted their price target on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $159.45.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $0.55 during mid-day trading on Tuesday, hitting $99.70. The company had a trading volume of 1,492,952 shares, compared to its average volume of 2,372,630. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business's 50-day simple moving average is $131.80 and its 200-day simple moving average is $134.75. Illumina, Inc. has a 12 month low of $99.35 and a 12 month high of $156.66. The firm has a market cap of $15.81 billion, a P/E ratio of -12.99 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. As a group, analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.